Literature DB >> 18386230

VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.

Kristen Biggers1, Noah Scheinfeld.   

Abstract

Viventia Biotech Inc, under license from the University of Zurich, is developing VB4-845, comprising a Pseudomonas exotoxin fused to an anti-epithelial cell adhesion molecule single-chain antibody fragment, for the potential treatment of head and neck cancer (intratumoral) and bladder cancer (intravesical). VB4-845 is currently undergoing phase II and III clinical trials in patients with head and neck squamous cell carcinomas, as well as phase II clinical trials for the treatment of superficial transitional cell carcinoma of the bladder.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18386230

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  8 in total

Review 1.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

2.  HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

Authors:  Bart E C G de Goeij; Matthias Peipp; Simone de Haij; Edward N van den Brink; Christian Kellner; Thilo Riedl; Rob de Jong; Tom Vink; Kristin Strumane; Wim K Bleeker; Paul W H I Parren
Journal:  MAbs       Date:  2014-01-03       Impact factor: 5.857

Review 3.  Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.

Authors:  Francesco Giansanti; David J Flavell; Francesco Angelucci; Maria Serena Fabbrini; Rodolfo Ippoliti
Journal:  Toxins (Basel)       Date:  2018-02-13       Impact factor: 4.546

4.  Antibodies to watch in 2019.

Authors:  Hélène Kaplon; Janice M Reichert
Journal:  MAbs       Date:  2018-12-22       Impact factor: 5.857

Review 5.  Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect.

Authors:  Mohammad Heiat; Hamid Hashemi Yeganeh; Seyed Moayed Alavian; Ehsan Rezaie
Journal:  Toxins (Basel)       Date:  2021-10-11       Impact factor: 4.546

Review 6.  Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents.

Authors:  Akmal M Asrorov; Bahtiyor Muhitdinov; Bin Tu; Sharafitdin Mirzaakhmedov; Huiyuan Wang; Yongzhuo Huang
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

7.  CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

Authors:  Ralph F Alderson; Robert J Kreitman; Tianling Chen; Peter Yeung; Ronald Herbst; Judy A Fox; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 13.801

Review 8.  Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.

Authors:  Yu-Chin Liu; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.